Updated September 2026Half off, onceTryozi review
The opening figure is the first four weeks, at half the standing rate.
The verdict
Tryozi opens on $139 and doubles it a screen later. The pricing block states the arrangement in full: $139 for the first four weeks, then $279 a month for compounded semaglutide. Tirzepatide runs $189 then $379. The standing rate is never concealed, only placed second.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- States
- 50
- From
- From $279/mo
- Dose published
- No
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Pharmacy
- Not named
- Availability
- All 50 states
- LegitScript
- Claimed by provider
Tryozi is a cash-pay telehealth storefront selling compounded semaglutide and compounded tirzepatide by weekly injection. Both are described as prepared by a licensed 503A U.S. pharmacy. Nothing else is listed. The platform states LegitScript certification and links its own listing.
Who writes the prescription, and what do they see?
Every request is stated to be reviewed by a licensed U.S. clinician rather than a bot, which the site says in those words. Eligibility is checked through a free two-minute assessment before any charge. No individual clinician, medical group or medical director is named. What a clinician reads before prescribing is not described.
Multi-week plans are billed once and ship every four weeks, so a fill arrives thirteen times a year rather than twelve. Discounts on the twelve-, twenty-four- and fifty-two-week terms are published as percentages off. The full total is stated to be shown before payment. Ongoing support is described without a stated cadence.
What happens when the dose goes up?
No dose tier is published and no milligram figure appears beside either product. Each card explains what its molecule acts on, with semaglutide described as one appetite pathway and tirzepatide as two. Nothing states whether the rate moves as the dose climbs. Who approves a step up is not addressed.
What the price includes
Semaglutide is $139 for the first four weeks and $279 a month after. Tirzepatide is $189 then $379, on the same halving. Longer terms are billed in one charge at published percentage discounts, each shipping every four weeks. The recurring figure sits directly beneath the promotional one on the same card.
What it claims, and what it cites
Both lines are compounded rather than manufactured, and the preparing pharmacy is described as a licensed 503A facility without being named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. Each product card sets out the mechanism claimed for its molecule.
Where it holds up, and where it does not
- Strength: The recurring rate sits under the promotional one
- Strength: Every plan discount is published as a percentage
- Strength: The pharmacy type is stated as licensed 503A
- Strength: LegitScript certification is stated and linked
- Strength: Eligibility is checked before any charge
- Limitation: The headline is a first-fill rate, not the price
- Limitation: The standing rate is double the opening one
- Limitation: Fills arrive every four weeks, not monthly
- Limitation: No milligram dose appears on either card
- Limitation: No clinician or medical group is named
What the evidence says about this kind of treatment
The assessment above is about Tryozi. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A buyer who wants the recurring rate and the discount ladder on one screen.
- Wrong for
- A buyer budgeting from the figure in the headline.
How Tryozi compares
| Seller | Who it suits | Go |
|---|---|---|
 Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | See Cielo → |
 Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | See Zappy Health → |
 EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | See EOS Health → |
More GLP-1 telehealth sellers reviews: Kin MedsKinaLaSara Medical GroupLean MedsLeanDoseLevelsRx
Sponsored alternative
Bodybuilding Health+
A reader unwilling to prepay a year before seeing how the drug goes
Check Bodybuilding Health+ availability →Frequently asked
- What happens after the first four weeks?
- The rate doubles. Semaglutide moves from $139 to $279 a month and tirzepatide from $189 to $379, as printed on the same card.
- Is a monthly plan billed every month?
- Multi-week plans are billed once and ship every four weeks, which is thirteen fills across a year rather than twelve.
- Does the price change with the dose?
- Nothing on the page says. No dose tier or milligram figure is published beside either product.
- Is Tryozi legit?
- Tryozi is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is Tryozi expensive compared with other GLP-1 telehealth sellers?
- Tryozi publishes a starting figure of $279/mo. Across the 252 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $399 with a median of $178, which puts Tryozi above the median. The other 19 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.